Mucosis BV, the first spin-off of Biomade Technology Foundation, has successfully completed a € 3 million Series A round of financing in September 2007. A consortium consisting of BioGeneration Ventures (lead investor), MedSciences Capital, and NV NOM (Investment and Development Agency for the Northern Netherlands) participated in this equity investment. The round of financing enables Mucosis to advance its innovative vaccine development platform into the clinic.
About Biogeneration Ventures B.V.
BioGeneration Ventures (www.biogenerationventures.com) invests in Dutch life sciences companies. BioGeneration Ventures was co-founded by the Netherlands Genomics Initiative (NGI), NWO, the holding of the University of Leiden, and ABN-AMRO Capital. BioGeneration closely cooperates with Forbion Capital Partners.
About MedSciences Capital
MedSciences Capital (www.medsciencescapital.com) is an Amsterdam-based group of venture capital funds investing in early-to mid-stage medical life sciences companies. The investment in Mucosis was made through MedSciences Seed Fund b.v. .
About NV NOM
NOM (www.nom.nl) provides risk-bearing capital and participates in companies in the Northern Netherlands. The NV NOM participates in Mucosis via its 100% subsidiary, Venture Capital Fund III.